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* For some secondary prevention trials, the numbers of events have been updated slightly from those published 
previously (BMJ 1994; BMJ 2002). Specifically, the current report includes an additional 5 vs 8 (aspirin vs adjusted 
control) non-fatal myocardial infarctions, 13 vs 18 non-fatal strokes, 16 vs 26 serious vascular events (AICLA [0 vs 2], 
AMIS [3 vs 2], Canadian Co-op [1 vs 0] and UKTIA [12 vs 11x2]), and 2 vs 1 major extracranial bleeds (Britton [0 vs 1] 
and UKTIA [2 vs 0]). (Two aspirin-allocated patients had both a non-fatal MI and a non-fatal stroke.) These events were 
previously omitted from the 2002 report because an earlier definition (BMJ 1994) of a non-fatal event was applied in 
error. None of these minor changes affect the conclusions of previous reports.  
 
 
 
Web Table 1: Baseline characteristics of the primary and secondary prevention trials 
 
 
Number of 
participants Male
Age, 
years
Blood pressure 
(SBP/DBP), mmHg
Total cholesterol, 
mmol/L
Current 
smokers
Body mass index, 
kg/m2
Diabetes 
mellitus Hypertension 
Any vascular 
disease 
Primary prevention trials           
British Doctors Study  5139 100% 61 (7) 136 (17) / 83 (10) - 31% 24.4 (2.5) 2% 10% 8% 
US Physicians Health Study 22071 100% 53 (10) 126 (12) / 79 (8) 5.5 (1.2) 11% 24.9 (3.0) 2% 24% 1% 
Thrombosis Prevention Trial 5085 100% 57 (7) 139 (18) / 83 (10) 6.4 (1.0) 41% 27.4 (3.6) 2% 16% <1% 
Hypertension Optimal Treatment Trial 18790 53% 61 (7) 170 (14) / 105 (3) 6.0 (1.1) 16% 28.4 (4.7) 8% 100% 3% 
Primary Prevention Project 4495 43% 64 (8) 145 (16) / 85 (8) 6.1 (1.2) 15% 27.6 (4.7) 17% 68% 4% 
Women's Health Study 39876 0% 54 (7) 124 (13) / 77 (8)* 5.2 (1.0)* 13% 26.0 (5.1) 3% 26% <1% 
Subtotal: 6 trials 95456 46% 56 (9) 136 (22) / 84 (13) 5.6 (1.1) 16% 26.3 (4.6) 4% 41% 2% 
Secondary prevention post-MI trials   
Cardiff-I 1239 100% 55 (8) - - - - - - 100% 
Cardiff-II 1725 85% 56 (10) 143 (29) / 90 (18) - - - 5% - 100% 
PARIS-I  1216 87% 56 (8) 132 (18) / 83 (9) - - - 10% - 100% 
AMIS 4524 89% 55 (8) 128 (16) / 80 (9) - - - 11% - 100% 
CDP-A 1529 100% 56 (7) 132 (18) / 81 (10) - - - 14% - 100% 
Gamis 626 78% 59 (7) - - - - 20% 19% 100% 
Subtotal: 6 trials 10859 90% 56 (8) 132 (21) / 82 (12) - - - 11% 19% 100% 
Secondary prevention post TIA / stroke trials   
AITIA 319 70% 58 (14) - - - - - - 100% 
UK-TIA  2435 73% 60 (9) 151 (25) / 88 (12) - - - 4% 27% 100% 
Reuther 60 65% 58 (10) - - - - 17% 50% 100% 
CA Co-op 283 67% 61 (9) 146 (23) / 85 (11) - - - 8% 37% 100% 
Toulouse TIA 303 86% 63 (9) - - - - - - 100% 
AICLA 402 68% 64 (10) 150 (21) / 90 (12) - - - 23% 64% 100% 
Danish Co-op 203 73% 59 (9) 138 (22) / 84 (12) - - - 6% - 100% 
Britton 505 62% 68 (10) - - - - 17% 46% 100% 
Danish Low Dose 301 65% 59 (8) 149 (23) / 85 (12) - - - 7% - 100% 
SALT 1359 66% 67 (7) - - - - 13% 47% 100% 
Subtotal: 10 trials 6170 70% 62 (10) 149 (24) / 87 (12) - - 9% 38% 100% 
 
- = Not available, MI = myocardial infarction, TIA = transient ischaemic attack. * In the Women's Health Study, individual blood pressure and cholesterol levels were imputed based on categories provided by the investigators (in 10 mmHg 
ranges for SBP, 5 mmHg ranges for DBP and 10 mg/dL [~0.25 mmol/L] ranges for cholesterol). Continuous data are presented as mean (SD). Percentages are based on the proportions among those participants with data available. Some patients
 in the primary prevention trials were found, after randomisation, to have had vascular disease (i.e. prior history of myocardial infarction, cerebrovascular disease, angina pectoris, peripheral arterial disease or heart failure).
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Web Table 2: Number of events in the primary and secondary prevention trials 
 
Mortality 
Trial 
Serious 
vascular 
event 
Major 
coronary 
events
Non fatal 
myocardial 
infarction
Any 
stroke
Stroke of 
unknown 
cause CHD Stroke 
Other 
vascular
Any 
known 
  vascular
Non 
vascular
Unknown 
cause All causes
Major 
extracranial 
bleed Fatal bleed 
Primary prevention trials     
British Doctors Study (2:1†) 434 267 149 133 87 136 42 46 224 194 3 421 30 4 
US Physicians Health Study 686 459 342 219 10 127 22 28 177 205 62 444 78 2 
Thrombosis Prevention Trial 468 353 233 100 22 141 25 28 194 197 48 439 33 5 
Hypertension Optimal Treatment Trial 712 345 182 317 291 170‡ 51 63 284 305 0 589 176 10 
Primary Prevention Project 112 46 36 39 6 10 7 35 52 76 12 140 9 4 
Women's Health Study 999 493 365 487 4 134 58 55 247 850 154 1251 218 1 
Subtotal: 6 trials 3411 1963 1307 1295 420 718 205 255 1178 1827 279 3284 544 26 
Secondary prevention post-MI trials     
Cardiff-I 133 129 25 1 0 104 1 2 107 6 1 114 0 0 
Cardiff-II 316 306 96 10 7 206 10 4 220 10 0 230 0 0 
PARIS-I (2:1†) 212 195 84 20 18 110 5 3 118 19 0 137 0 0 
AMIS 795 707 317 101 97 388 10 10 408 52 5 465 0 0 
CDP-A 178 146 59 25 24 85 5 14 104 6 0 110 0 0 
Gamis 78 61 26 2 0 35 2 7 44 7 8 59 0 0 
Subtotal: 6 trials 1712 1544 607 159 146 928 33 40 1001 100 14 1115 0 0 
Secondary prevention post TIA / stroke trials    
AITIA 61 17 6 40 39 7 6 10 23 3 0 26 3 0 
UK-TIA (2:1†) 558 245 77 320 224 163 55 35 253 77 13 343 15 2 
Reuther 7 1 0 6 4 1 2 0 3 0 0 3 1 0 
CA Co-op 63 16 4 43 43 12 9 5 26 5 0 31 0 0 
Toulouse TIA 27 7 2 16 16 5 5 4 14 11 0 25 0 0 
AICLA 79 15 11 53 49 4 6 5 15 12 10 37 0 0 
Danish Co-op 50 20 10 32 29 10 4 1 15 5 1 21 0 0 
Britton 114 42 21 63 15 15 20 22 57 14 0 71 5 0 
Danish Low Dose 42 16 2 21 20 14 1 3 18 4 2 24 0 0 
SALT 307 119 53 180 11 54 32 34 120 35 5 160 4 0 
Subtotal: 10 trials 1308 498 186 774 450 285 140 119 544 166 31 741 28 2 
 
† Allocation ratio 2:1; in tables or figures where adjusted numbers of controls are given, the number of events in the control group of this study is doubled. ‡Includes 149 sudden deaths.  
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Web Table 3: Rate ratios associated with risk factors for selected outcomes among people with no known vascular disease in primary prevention trials
Variable
Serious vascular
event Non fatal MI CHD death
Major coronary
event
Probably
ischaemic stroke
Haemorrhagic
stroke Any stroke
Non fatal MI or
probably
ischaemic stroke
Major GI or
other
extracranial
bleed
Non fatal major
GI or other
extracranial
bleed
Age, per decade 2.08 (1.99,2.17) 1.63 (1.52,1.75) 2.37 (2.15,2.62) 1.84 (1.74,1.95) 2.46 (2.27,2.65) 1.59 (1.33,1.90) 2.29 (2.13,2.46) 1.91 (1.81,2.02) 2.15 (1.93,2.39) 2.10 (1.88,2.34)
Male gender * 1.86 (1.60,2.16) 2.58 (1.91,3.49) 2.21 (1.58,3.07) 2.43 (1.94,3.04) 1.44 (1.14,1.82) 1.11 (0.52,2.34) 1.39 (1.12,1.74) 1.85 (1.52,2.24) 1.99 (1.45,2.73) 1.98 (1.42,2.75)
Diabetes 2.43 (2.16,2.74) 2.80 (2.31,3.40) 2.42 (1.86,3.15) 2.66 (2.28,3.12) 2.06 (1.67,2.54) 1.74 (0.95,3.17) 2.02 (1.66,2.46) 2.39 (2.06,2.78) 1.55 (1.13,2.14) 1.55 (1.11,2.16)
Current smoker 2.03 (1.87,2.20) 1.96 (1.72,2.23) 2.17 (1.83,2.58) 2.05 (1.85,2.28) 2.00 (1.72,2.31) 2.18 (1.57,3.02) 2.02 (1.77,2.31) 1.97 (1.78,2.17) 1.56 (1.25,1.94) 1.50 (1.20,1.88)
Mean blood pressure 1.79 (1.67,1.92) 1.59 (1.42,1.77) 2.10 (1.83,2.42) 1.73 (1.59,1.89) 2.00 (1.77,2.26) 2.18 (1.65,2.87) 2.02 (1.81,2.26) 1.76 (1.62,1.92) 1.32 (1.09,1.58) 1.32 (1.09,1.60)
Cholesterol 1.10 (1.06,1.14) 1.23 (1.16,1.31) 1.09 (1.00,1.18) 1.18 (1.12,1.24) 1.02 (0.95,1.09) 0.90 (0.77,1.07) 1.00 (0.94,1.06) 1.13 (1.08,1.19) 0.99 (0.90,1.08) 0.98 (0.89,1.08)
BMI (per 5 kg/m²) 1.07 (1.02,1.11) 1.10 (1.03,1.18) 1.07 (0.97,1.18) 1.09 (1.03,1.15) 1.06 (0.98,1.14) 0.85 (0.71,1.02) 1.02 (0.96,1.09) 1.08 (1.03,1.14) 1.24 (1.13,1.35) 1.22 (1.11,1.34)
* The relevance of male gender can be assessed only in the two trials that included both men and women, so the confidence intervals for its relevance are wide, particularly for stroke.
GI = Gastrointestinal.
Total cholesterol was not available in the British Doctors Study.
Excluding the 2% of participants with known history of vascular disease.
Rate ratios for cholesterol are per 1mmol/L and for mean blood pressure per 20mmHg.
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Subgroup
Events (% per annum)
Allocated
aspirin control
Ratio of annual event rates (& CI)
Aspirin : Control
Age; years (χ2
 1 = 0·1; P = 0·8)
< 65 592 716
(0·21%/y) (0·25%/y)
0·81 (0·70    0·94)
65+ 342 399
(0·67%/y) (0·79%/y)
0·83 (0·68    1·02)
Gender (χ2
 1 = 4·7; P = 0·03)
Male 635 801
(0·57%/y) (0·72%/y)
0·77 (0·67    0·89)
Female 299 314
(0·14%/y) (0·14%/y)
0·95 (0·77    1·17)
Prior vascular disease (χ2
 1 = 0·2; P = 0·6)
Yes 66 81
(1·63%/y) (1·99%/y)
0·76 (0·48    1·21)
No 868 1034
(0·26%/y) (0·32%/y)
0·83 (0·73    0·93)
Prior diabetes (χ2
 1 = 0·8; P = 0·4)
Yes 101 107
(0·93%/y) (1·01%/y)
0·92 (0·64    1·32)
No 775 944
(0·24%/y) (0·30%/y)
0·81 (0·71    0·92)
Prior hypertension (χ2
 1 = 0·1; P = 0·7)
Yes 456 552
(0·42%/y) (0·51%/y)
0·81 (0·69    0·96)
No 478 561
(0·21%/y) (0·25%/y)
0·84 (0·71    0·99)
Current smoker (χ2
 1 = 3·6; P = 0·06)
Yes 303 327
(0·60%/y) (0·64%/y)
0·94 (0·76    1·16)
No 630 785
(0·22%/y) (0·28%/y)
0·78 (0·68    0·90)
SBP; mm Hg (trend χ2
 1 = 0·2; P = 0·7)
< 140 396 480
(0·17%/y) (0·21%/y)
0·82 (0·69    0·98)
140 − 159 256 307
(0·49%/y) (0·59%/y)
0·80 (0·64    1·00)
160+ 229 259
(0·65%/y) (0·75%/y)
0·87 (0·68    1·10)
DBP; mm Hg (trend χ2
 1 = 0·1; P = 0·8)
< 80 259 303
(0·14%/y) (0·17%/y)
0·83 (0·67    1·03)
80 − 89 284 323
(0·41%/y) (0·47%/y)
0·85 (0·68    1·05)
90+ 338 420
(0·50%/y) (0·62%/y)
0·81 (0·66    0·98)
Cholesterol; mmol/l (trend χ2
 1 = 0·6; P = 0·5)
< 5·0 119 171
(0·13%/y) (0·18%/y)
0·70 (0·52    0·95)
5·0 − 5·9 183 223
(0·21%/y) (0·25%/y)
0·82 (0·64    1·06)
6·0+ 282 347
(0·45%/y) (0·57%/y)
0·80 (0·65    0·98)
BMI; kg/m² (trend χ2
 1 = 0·0; P = 1·0)
< 25·0 364 435
(0·23%/y) (0·28%/y)
0·81 (0·67    0·97)
25·0 − 29·9 405 480
(0·35%/y) (0·41%/y)
0·84 (0·71    1·01)
30·0+ 149 187
(0·27%/y) (0·34%/y)
0·79 (0·60    1·05)
Predicted 5−year CHD risk*; % (trend χ2
 1 = 0·0; P = 1·0)
< 2·5 383 438
(0·14%/y) (0·16%/y)
0·86 (0·72    1·03)
2·5, < 5 226 285
(0·62%/y) (0·79%/y)
0·76 (0·60    0·97)
5, < 10 188 241
(1·14%/y) (1·43%/y)
0·78 (0·60    1·01)
10+ 71 70
(1·89%/y) (1·85%/y)
1·06 (0·67    1·67)
934 1115(0·28%/y) (0·34%/y) 0·82 (0·75 

 0·90)
P = 0·00002
  Total
Adjusted
Web Figure 1: MAJOR CORONARY EVENTS in primary prevention trials 
subgroup analyses
99% or 95% confidence intervals
0·5 0·75 1·0 1·25 1·5
Aspirin better Aspirin worse
Treatment effect P = 0·00002
Global heterogeneity on 11 df: χ2
 11 = 10·4; P = 0·5
N.B. Unknown values not plotted
* Excluding patients with history of vascular disease
15:58:11   17 March 2009
Not for publication or citation
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Study
Events (% per annum)
Allocated
aspirin control
Ratio of annual event rates (& CI)
Aspirin : Control
(a) Non−fatal MI (χ2
 5 = 20·4; P = 0·001)
British Doctors’ Study 104 90
(0·54%/y) (0·47%/y)
1·15 (0·73    1·79)
US Physicians’ Health
Study
129 213
(0·24%/y) (0·39%/y)
0·61 (0·46    0·81)
Thrombosis Prevention
Trial
96 137
(0·58%/y) (0·83%/y)
0·70 (0·50    0·98)
Hypertension Optimal
Treatment Trial
68 114
(0·19%/y) (0·32%/y)
0·60 (0·41    0·88)
Primary Prevention Project 15 21
(0·18%/y) (0·25%/y)
0·72 (0·31    1·71)
Women’s Health Study 184 181
(0·09%/y) (0·09%/y)
1·02 (0·78    1·33)
596 756(0·18%/y) (0·23%/y) 0·77 (0·69 

 0·86)
P < 0·00001
  (a) Subtotal
(b) CHD death (χ2
 5 = 3·7; P = 0·6)
British Doctors’ Study 89 94
(0·46%/y) (0·49%/y)
0·94 (0·59    1·50)
US Physicians’ Health
Study
60 67
(0·11%/y) (0·12%/y)
0·90 (0·57    1·41)
Thrombosis Prevention
Trial
78 63
(0·46%/y) (0·37%/y)
1·25 (0·81    1·92)
Hypertension Optimal
Treatment Trial
80 90
(0·22%/y) (0·25%/y)
0·89 (0·60    1·32)
Primary Prevention Project 4 6
(0·05%/y) (0·07%/y)
0·68 (0·13    3·46)
Women’s Health Study 61 73
(0·03%/y) (0·04%/y)
0·84 (0·54    1·30)
372 393(0·11%/y) (0·12%/y) 0·95 (0·82 

 1·10)
P = 0·5
  (b) Subtotal
(a or b) Major coronary event (χ2
 5 = 12·6; P = 0·03)
British Doctors’ Study 181 172
(0·95%/y) (0·90%/y)
1·05 (0·75    1·46)
US Physicians’ Health
Study
186 273
(0·34%/y) (0·50%/y)
0·68 (0·54    0·87)
Thrombosis Prevention
Trial
160 193
(0·97%/y) (1·17%/y)
0·82 (0·63    1·08)
Hypertension Optimal
Treatment Trial
145 200
(0·41%/y) (0·57%/y)
0·72 (0·55    0·95)
Primary Prevention Project 19 27
(0·23%/y) (0·33%/y)
0·71 (0·33    1·52)
Women’s Health Study 243 250
(0·12%/y) (0·13%/y)
0·97 (0·77    1·23)
934 1115(0·28%/y) (0·34%/y) 0·82 (0·75 

 0·90)
P = 0·00002
  (a or b) Total
Adjusted
Web Figure 2: MAJOR CORONARY EVENTS in primary prevention trials, by study 
99% or 95% confidence intervals
0·5 0·75 1·0 1·25 1·5
Aspirin better Aspirin worse
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Study
Events (% per annum)
Allocated
aspirin control
Ratio of annual event rates (& CI)
Aspirin : Control
(a) Haemorrhagic first stroke (χ2
 5 = 4·7; P = 0·5)
British Doctors’ Study 13 14
(0·07%/y) (0·07%/y)
0·92 (0·27    3·13)
US Physicians’ Health
Study
24 12
(0·04%/y) (0·02%/y)
1·95 (0·83    4·60)
Thrombosis Prevention
Trial †
14 6
(0·08%/y) (0·04%/y)
2·23 (0·71    7·07)
Hypertension Optimal
Treatment Trial
12 14
(0·03%/y) (0·04%/y)
0·85 (0·31    2·35)
Primary Prevention Project 2 2
(0·02%/y) (0·02%/y)
1·01 (0·08    13·32)
Women’s Health Study 51 41
(0·03%/y) (0·02%/y)
1·24 (0·73    2·12)
116 89(0·04%/y) (0·03%/y)
1·32 (1·00   1·75)
adverse
P = 0·05
  (a) Subtotal
(b) Ischaemic first stroke (χ2
 4 = 6·1; P = 0·2)
British Doctors’ Study 19 14
(0·10%/y) (0·07%/y)
1·33 (0·45    3·88)
US Physicians’ Health
Study
91 82
(0·17%/y) (0·15%/y)
1·11 (0·75    1·64)
Thrombosis Prevention
Trial †
23 35
(0·14%/y) (0·21%/y)
0·67 (0·34    1·31)
Hypertension Optimal
Treatment Trial ††
Primary Prevention Project 14 15
(0·17%/y) (0·18%/y)
0·95 (0·36    2·47)
Women’s Health Study 170 221
(0·09%/y) (0·11%/y)
0·77 (0·59    1·00)
317 367(0·11%/y) (0·12%/y) 0·86 (0·74 

 1·00)
P = 0·05
  (b) Subtotal
(c) Any first stroke, including unknown type (χ2
 5 = 7·4; P = 0·2)
British Doctors’ Study 91 84
(0·47%/y) (0·44%/y)
1·08 (0·67    1·73)
US Physicians’ Health
Study
121 98
(0·22%/y) (0·18%/y)
1·23 (0·87    1·75)
Thrombosis Prevention
Trial †
50 50
(0·30%/y) (0·30%/y)
1·01 (0·60    1·69)
Hypertension Optimal
Treatment Trial
156 161
(0·44%/y) (0·46%/y)
0·97 (0·72    1·29)
Primary Prevention Project 16 23
(0·20%/y) (0·28%/y)
0·71 (0·31    1·62)
Women’s Health Study 221 266
(0·11%/y) (0·13%/y)
0·83 (0·66    1·05)
655 682(0·20%/y) (0·21%/y) 0·95 (0·85 

 1·06)
P = 0·4; NS
  (c) Total
Adjusted
Web Figure 3: STROKE SUBTYPES (first stroke only) in primary prevention trials, by study 
99% or 95% confidence intervals
0 0·5 1·0 1·5 2·0
Aspirin better Aspirin worseHeterogeneity (a) vs. (b): χ2
 1 = 7·1; P = 0·008
† Aspirin vs. control in the half not allocated warfarin in TPT: 4 vs. 2 haemorrhagic, 12 vs. 19 ischaemic and 5 vs. 6
unknown strokes. 
†† Non−haemorrhagic strokes in HOT were not further subdivided.
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Subgroup
Events (% per annum)
Allocated
aspirin control
Ratio of annual event rates (& CI)
Aspirin : Control
Age; years (χ2
 1 = 0·0; P = 0·9)
< 65 284 313
(0·10%/y) (0·11%/y)
0·91 (0·73    1·12)
65+ 255 280
(0·50%/y) (0·56%/y)
0·89 (0·71    1·12)
Gender (χ2
 1 = 8·0; P = 0·005)
Male 312 292
(0·28%/y) (0·26%/y)
1·06 (0·85    1·32)
Female 227 301
(0·10%/y) (0·14%/y)
0·75 (0·60    0·94)
Prior vascular disease (χ2
 1 = 3·4; P = 0·07)
Yes 45 30
(1·13%/y) (0·72%/y)
1·38 (0·74    2·57)
No 494 563
(0·15%/y) (0·17%/y)
0·87 (0·74    1·03)
Prior diabetes (χ2
 1 = 0·3; P = 0·6)
Yes 56 66
(0·51%/y) (0·62%/y)
0·81 (0·51    1·30)
No 468 513
(0·15%/y) (0·16%/y)
0·90 (0·76    1·07)
Prior hypertension (χ2
 1 = 0·0; P = 0·9)
Yes 329 362
(0·30%/y) (0·34%/y)
0·90 (0·74    1·09)
No 208 231
(0·09%/y) (0·10%/y)
0·89 (0·69    1·15)
Current smoker (χ2
 1 = 5·1; P = 0·02)
Yes 158 143
(0·31%/y) (0·28%/y)
1·13 (0·83    1·54)
No 378 449
(0·13%/y) (0·16%/y)
0·83 (0·69    0·99)
SBP; mm Hg (trend χ2
 1 = 0·0; P = 1·0)
< 140 181 220
(0·08%/y) (0·09%/y)
0·83 (0·64    1·08)
140 − 159 160 165
(0·30%/y) (0·32%/y)
0·95 (0·71    1·27)
160+ 160 186
(0·45%/y) (0·54%/y)
0·83 (0·63    1·10)
DBP; mm Hg (trend χ2
 1 = 1·2; P = 0·3)
< 80 136 179
(0·07%/y) (0·10%/y)
0·76 (0·57    1·01)
80 − 89 123 124
(0·18%/y) (0·18%/y)
0·96 (0·69    1·34)
90+ 241 268
(0·36%/y) (0·40%/y)
0·90 (0·71    1·14)
Cholesterol; mmol/l (trend χ2
 1 = 0·1; P = 0·7)
< 5·0 108 119
(0·11%/y) (0·12%/y)
0·92 (0·65    1·30)
5·0 − 5·9 128 147
(0·14%/y) (0·16%/y)
0·87 (0·64    1·18)
6·0+ 137 156
(0·22%/y) (0·26%/y)
0·86 (0·64    1·16)
BMI; kg/m² (trend χ2
 1 = 0·0; P = 0·9)
< 25·0 214 235
(0·14%/y) (0·15%/y)
0·87 (0·68    1·12)
25·0 − 29·9 217 233
(0·19%/y) (0·20%/y)
0·94 (0·74    1·21)
30·0+ 102 122
(0·19%/y) (0·22%/y)
0·84 (0·59    1·18)
Predicted 5−year CHD risk*; % (trend χ2
 1 = 3·9; P = 0·05)
< 2·5 242 301
(0·09%/y) (0·11%/y)
0·80 (0·64    1·00)
2·5, < 5 100 114
(0·27%/y) (0·32%/y)
0·85 (0·60    1·22)
5, < 10 104 106
(0·63%/y) (0·62%/y)
1·04 (0·72    1·52)
10+ 48 42
(1·29%/y) (1·11%/y)
1·15 (0·65    2·04)
539 593(0·16%/y) (0·18%/y) 0·90 (0·80 

 1·01)
P = 0·08
  Total
Adjusted
Web Figure 4: PROBABLY ISCHAEMIC STROKE in primary prevention trials 
subgroup analyses
99% or 95% confidence intervals
0·5 0·75 1·0 1·25 1·5
Aspirin better Aspirin worse
Treatment effect P = 0·08
Global heterogeneity on 11 df: χ2
 11 = 22·0; P = 0·02
N.B. Unknown values not plotted
* Excluding patients with history of vascular disease
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Subgroup
Events (% per annum)
Allocated
aspirin control
Ratio of annual event rates (& CI)
Aspirin : Control
Age; years (χ2
 1 = 0·1; P = 0·8)
< 65 358 382
(0·13%/y) (0·14%/y)
0·94 (0·78    1·14)
65+ 297 300
(0·59%/y) (0·60%/y)
0·97 (0·78    1·20)
Gender (χ2
 1 = 8·3; P = 0·004)
Male 371 332
(0·33%/y) (0·30%/y)
1·12 (0·91    1·37)
Female 284 350
(0·13%/y) (0·16%/y)
0·81 (0·66    0·99)
Prior vascular disease (χ2
 1 = 4·1; P = 0·04)
Yes 51 31
(1·28%/y) (0·74%/y)
1·50 (0·83    2·72)
No 604 651
(0·18%/y) (0·20%/y)
0·93 (0·80    1·08)
Prior diabetes (χ2
 1 = 0·8; P = 0·4)
Yes 62 73
(0·56%/y) (0·69%/y)
0·82 (0·52    1·28)
No 576 594
(0·18%/y) (0·19%/y)
0·96 (0·83    1·13)
Prior hypertension (χ2
 1 = 0·1; P = 0·8)
Yes 378 398
(0·35%/y) (0·37%/y)
0·94 (0·78    1·13)
No 275 284
(0·12%/y) (0·13%/y)
0·97 (0·77    1·21)
Current smoker (χ2
 1 = 3·9; P = 0·05)
Yes 191 171
(0·38%/y) (0·33%/y)
1·14 (0·86    1·51)
No 460 510
(0·16%/y) (0·18%/y)
0·89 (0·75    1·05)
SBP; mm Hg (trend χ2
 1 = 0·1; P = 0·8)
< 140 243 267
(0·11%/y) (0·11%/y)
0·92 (0·73    1·16)
140 − 159 184 184
(0·35%/y) (0·35%/y)
0·98 (0·75    1·29)
160+ 185 203
(0·53%/y) (0·59%/y)
0·88 (0·67    1·14)
DBP; mm Hg (trend χ2
 1 = 0·7; P = 0·4)
< 80 180 214
(0·10%/y) (0·12%/y)
0·84 (0·65    1·09)
80 − 89 152 147
(0·22%/y) (0·21%/y)
1·01 (0·75    1·37)
90+ 279 294
(0·42%/y) (0·44%/y)
0·95 (0·76    1·18)
Cholesterol; mmol/l (trend χ2
 1 = 0·6; P = 0·4)
< 5·0 139 141
(0·15%/y) (0·15%/y)
1·00 (0·73    1·36)
5·0 − 5·9 154 168
(0·17%/y) (0·19%/y)
0·91 (0·69    1·22)
6·0+ 160 178
(0·25%/y) (0·29%/y)
0·88 (0·67    1·17)
BMI; kg/m² (trend χ2
 1 = 0·0; P = 1·0)
< 25·0 265 285
(0·17%/y) (0·18%/y)
0·90 (0·72    1·13)
25·0 − 29·9 267 261
(0·23%/y) (0·22%/y)
1·04 (0·83    1·31)
30·0+ 115 133
(0·21%/y) (0·24%/y)
0·86 (0·62    1·20)
Predicted 5−year CHD risk*; % (trend χ2
 1 = 5·0; P = 0·03)
< 2·5 305 355
(0·11%/y) (0·13%/y)
0·86 (0·70    1·05)
2·5, < 5 122 136
(0·33%/y) (0·38%/y)
0·89 (0·64    1·23)
5, < 10 120 115
(0·73%/y) (0·68%/y)
1·11 (0·78    1·58)
10+ 57 45
(1·53%/y) (1·18%/y)
1·30 (0·76    2·22)
655 682(0·20%/y) (0·21%/y) 0·95 (0·85 

 1·06)
P = 0·4
  Total
Adjusted
Web Figure 5: FIRST STROKE (any type) in primary prevention trials     
subgroup analyses
99% or 95% confidence intervals
0·5 0·75 1·0 1·25 1·5
Aspirin better Aspirin worse
Treatment effect P = 0·4
Global heterogeneity on 11 df: χ2
 11 = 23·7; P = 0·01
N.B. Unknown values not plotted
* Excluding patients with history of vascular disease
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Study
Events (% per annum)
Allocated
aspirin control
Ratio of annual event rates (& CI)
Aspirin : Control
British Doctors’ Study 20 20
(0·10%/y) (0·10%/y)
1·00 (0·37    2·70)
US Physicians’ Health
Study
48 30
(0·09%/y) (0·05%/y)
1·59 (0·89    2·84)
Thrombosis Prevention
Trial
20 13
(0·12%/y) (0·08%/y)
1·54 (0·63    3·77)
Hypertension Optimal
Treatment Trial
114 62
(0·32%/y) (0·18%/y)
1·81 (1·22    2·66)
Primary Prevention Project 6 3
(0·07%/y) (0·04%/y)
1·98 (0·36    11·02)
Women’s Health Study 127 91
(0·06%/y) (0·05%/y)
1·39 (0·98    1·97)
335 219(0·10%/y) (0·07%/y)
1·54 (1·30   1·82)
adverse
P < 0·00001
  Total †
Adjusted
Web Figure 6: GASTRO−INTESTINAL BLEED (or other major extracranial bleed) 
     in primary prevention trials, by study 
99% or 95% confidence intervals
0 0·5 1·0 1·5 2·0
Aspirin better Aspirin worse
Treatment effect P < 0·00001, adverse
Heterogeneity between 6 trials: χ2
 5 = 3·1; P = 0·7
† Includes 9 vs. 20 fatal bleeds, P = 0·07 reduction.
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Subgroup
Events (% per annum)
Allocated
aspirin control
Ratio of annual event rates (& CI)
Aspirin : Control
Age; years (χ2
 1 = 0·0; P = 1·0)
< 65 206 134
(0·07%/y) (0·05%/y)
1·53 (1·16    2·03)
65+ 129 85
(0·25%/y) (0·17%/y)
1·55 (1·08    2·21)
Gender (χ2
 1 = 0·0; P = 0·9)
Male 166 108
(0·15%/y) (0·10%/y)
1·56 (1·13    2·15)
Female 169 111
(0·08%/y) (0·05%/y)
1·52 (1·11    2·06)
Prior vascular disease (χ2
 1 = 0·3; P = 0·6)
Yes 11 10
(0·27%/y) (0·24%/y)
1·17 (0·35    3·92)
No 324 209
(0·10%/y) (0·06%/y)
1·55 (1·24    1·95)
Prior diabetes (χ2
 1 = 1·5; P = 0·2)
Yes 25 22
(0·23%/y) (0·21%/y)
1·10 (0·52    2·34)
No 306 192
(0·10%/y) (0·06%/y)
1·60 (1·27    2·03)
Prior hypertension (χ2
 1 = 0·1; P = 0·8)
Yes 195 123
(0·18%/y) (0·11%/y)
1·57 (1·17    2·10)
No 140 96
(0·06%/y) (0·04%/y)
1·49 (1·06    2·10)
Current smoker (χ2
 1 = 1·9; P = 0·2)
Yes 65 56
(0·13%/y) (0·11%/y)
1·22 (0·75    1·98)
No 270 162
(0·10%/y) (0·06%/y)
1·64 (1·28    2·11)
SBP; mm Hg (trend χ2
 1 = 0·0; P = 0·9)
< 140 159 92
(0·07%/y) (0·04%/y)
1·72 (1·24    2·39)
140 − 159 66 55
(0·12%/y) (0·10%/y)
1·20 (0·74    1·92)
160+ 103 58
(0·29%/y) (0·17%/y)
1·76 (1·17    2·65)
DBP; mm Hg (trend χ2
 1 = 1·0; P = 0·3)
< 80 101 71
(0·06%/y) (0·04%/y)
1·41 (0·95    2·09)
80 − 89 76 48
(0·11%/y) (0·07%/y)
1·64 (1·02    2·64)
90+ 151 86
(0·22%/y) (0·13%/y)
1·72 (1·23    2·41)
Cholesterol; mmol/l (trend χ2
 1 = 5·6; P = 0·02)
< 5·0 77 53
(0·08%/y) (0·06%/y)
1·48 (0·94    2·32)
5·0 − 5·9 72 71
(0·08%/y) (0·08%/y)
1·02 (0·66    1·56)
6·0+ 113 41
(0·18%/y) (0·07%/y)
2·50 (1·65    3·79)
BMI; kg/m² (trend χ2
 1 = 0·6; P = 0·5)
< 25·0 106 77
(0·07%/y) (0·05%/y)
1·40 (0·95    2·07)
25·0 − 29·9 159 79
(0·14%/y) (0·07%/y)
1·99 (1·42    2·78)
30·0+ 66 60
(0·12%/y) (0·11%/y)
1·10 (0·70    1·75)
Predicted 5−year CHD risk*; % (trend χ2
 1 = 2·2; P = 0·1)
< 2·5 203 122
(0·07%/y) (0·04%/y)
1·64 (1·23    2·19)
2·5, < 5 69 40
(0·19%/y) (0·11%/y)
1·73 (1·05    2·86)
5, < 10 38 31
(0·23%/y) (0·18%/y)
1·25 (0·66    2·33)
10+ 14 16
(0·37%/y) (0·41%/y)
0·93 (0·34    2·52)
335 219(0·10%/y)(0·07%/y) 1·54 (1·30   1·82)
adverse
P < 0·00001
  Total
Adjusted
Web Figure 7: GASTRO−INTESTINAL BLEED (or other major extracranial bleed)
in primary prevention trials   subgroup analyses
99% or 95% confidence intervals
1·0 2·0 3·0
Aspirin better Aspirin worse
Treatment effect P < 0·00001, adverse
Global heterogeneity on 11 df: χ2
 11 = 13·2; P = 0·3
N.B. Unknown values not plotted
* Excluding patients with history of vascular disease
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Study
Events (% per annum)
Allocated
aspirin control
Ratio of annual event rates (& CI)
Aspirin : Control
(a) Post myocardial infarction
Cardiff−I 57 76
(8·81%/y) (12·30%/y)
0·72 (0·46    1·13)
Cardiff−II 129 187
(17·06%/y) (25·03%/y)
0·70 (0·52    0·93)
Paris−I 130 164
(5·24%/y) (6·86%/y)
0·76 (0·52    1·10)
AMIS 382 413
(5·80%/y) (6·41%/y)
0·89 (0·74    1·06)
CDP−A 76 102
(5·81%/y) (7·86%/y)
0·74 (0·50    1·09)
Gamis 33 45
(7·93%/y) (11·11%/y)
0·68 (0·37    1·27)
807 987(6·62%/y) (8·29%/y) 0·79 (0·72 

 0·87)
P < 0·00001
  (a) Subtotal
Heterogeneity between 6 trials: χ2
 5 = 4·7; P = 0·5
Micristin 65 106
(4·84%/y) (7·93%/y)
0·57 (0·38    0·87)
(b) Post transient ischaemic attack or stroke
AITIA 26 35
(12·38%/y) (18·52%/y)
0·67 (0·32    1·39)
UK−TIA 354 408
(5·98%/y) (7·03%/y)
0·85 (0·67    1·07)
Reuther 2 5
(3·45%/y) (8·93%/y)
0·42 (0·06    2·96)
CA Co−op 33 30
(9·51%/y) (8·70%/y)
1·08 (0·57    2·08)
Toulouse TIA 11 16
(2·62%/y) (3·33%/y)
0·73 (0·27    1·96)
AICLA 31 48
(5·70%/y) (9·23%/y)
0·63 (0·35    1·12)
Danish Co−op 23 27
(9·62%/y) (11·74%/y)
0·84 (0·41    1·75)
Britton 59 55
(13·69%/y) (12·97%/y)
1·05 (0·65    1·71)
Danish Low Dose 21 21
(7·64%/y) (7·75%/y)
0·98 (0·44    2·18)
SALT 138 169
(7·48%/y) (9·51%/y)
0·79 (0·59    1·06)
698 814(6·78%/y) (8·06%/y) 0·83 (0·75 

 0·93)
P = 0·001
  (b) Subtotal
Heterogeneity between 10 trials: χ2
 9 = 6·3; P = 0·7
ESPS−II 293 332
(8·88%/y) (10·07%/y)
0·86 (0·68    1·08)
1505 1801(6·69%/y) (8·19%/y) 0·81 (0·75 

 0·87)
P < 0·00001
  Total (a+b)
Adjusted
Web Figure 8: SERIOUS VASCULAR EVENTS in secondary prevention trials, by study 
99% or 95% confidence intervals
0·5 0·75 1·0 1·25 1·5
Aspirin better Aspirin worse
Treatment effect P < 0·00001
Difference between
treatment effects in 2 subtotals: χ2
 1 = 0·4; P = 0·5
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Study
Events (% per annum)
Allocated
aspirin control
Ratio of annual event rates (& CI)
Aspirin : Control
(a) Post myocardial infarction
Cardiff−I 10 15
(1·55%/y) (2·43%/y)
0·64 (0·23    1·79)
Cardiff−II 31 65
(4·08%/y) (8·67%/y)
0·49 (0·29    0·83)
Paris−I 50 68
(2·00%/y) (2·82%/y)
0·70 (0·38    1·27)
AMIS 142 175
(2·14%/y) (2·69%/y)
0·78 (0·58    1·04)
CDP−A 27 32
(2·05%/y) (2·45%/y)
0·84 (0·43    1·65)
Gamis 11 15
(2·64%/y) (3·70%/y)
0·71 (0·25    1·98)
271 370(2·21%/y) (3·08%/y) 0·71 (0·60 

 0·83)
P = 0·00003
  (a) Subtotal
Heterogeneity between 6 trials: χ2
 5 = 4·5; P = 0·5
Micristin 22 35
(1·64%/y) (2·62%/y)
0·62 (0·31    1·24)
(b) Post transient ischaemic attack or stroke
AITIA 4 2
(1·81%/y) (0·99%/y)
1·91 (0·23    15·89)
UK−TIA 42 70
(0·67%/y) (1·11%/y)
0·59 (0·31    1·09)
Reuther 0 0
(0·00%/y) (0·00%/y)
CA Co−op 4 0
(1·06%/y) (0·00%/y)
7·16 (0·54    94·17)
Toulouse TIA 0 2
(0·00%/y) (0·41%/y)
AICLA 2 9
(0·35%/y) (1·58%/y)
0·28 (0·06    1·32)
Danish Co−op 2 8
(0·76%/y) (3·24%/y)
0·30 (0·06    1·52)
Britton 11 10
(2·42%/y) (2·24%/y)
1·08 (0·35    3·32)
Danish Low Dose 0 2
(0·00%/y) (0·70%/y)
SALT 21 32
(1·08%/y) (1·66%/y)
0·65 (0·32    1·33)
86 135(0·79%/y) (1·24%/y) 0·64 (0·48 

 0·86)
P = 0·003
  (b) Subtotal
Heterogeneity between 9 trials: χ2
 8 = 14·8; P = 0·06
ESPS−II 17 22
(0·52%/y) (0·67%/y)
0·77 (0·34    1·77)
357 505(1·54%/y) (2·20%/y) 0·69 (0·60 

 0·80)
P < 0·00001
  Total (a+b)
Adjusted
Web Figure 9: NON−FATAL MYOCARDIAL INFARCTION in secondary prevention trials, by study 
99% or 95% confidence intervals
0·5 0·75 1·0 1·25
Aspirin better Aspirin better
Treatment effect P < 0·00001
Difference between
treatment effects in 2 subtotals: χ2
 1 = 0·4; P = 0·5
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Study
Deaths (% per annum)
Allocated
aspirin control
Ratio of annual death rates (& CI)
Aspirin : Control
(a) Post myocardial infarction
Cardiff−I 45 59
(6·87%/y) (9·31%/y)
0·74 (0·45    1·23)
Cardiff−II 89 117
(11·47%/y) (14·96%/y)
0·77 (0·54    1·11)
Paris−I 67 86
(2·58%/y) (3·34%/y)
0·77 (0·46    1·29)
AMIS 203 185
(2·96%/y) (2·71%/y)
1·06 (0·82    1·38)
CDP−A 37 48
(2·76%/y) (3·56%/y)
0·77 (0·44    1·35)
Gamis 13 22
(3·10%/y) (5·35%/y)
0·56 (0·23    1·38)
454 517(3·59%/y) (4·11%/y) 0·87 (0·76 

 0·99)
P = 0·04
  (a) Subtotal
Heterogeneity between 6 trials: χ2
 5 = 7·4; P = 0·2
Micristin 12 31
(0·89%/y) (2·32%/y)
0·40 (0·18    0·89)
(b) Post transient ischaemic attack or stroke
AITIA 4 3
(1·77%/y) (1·46%/y)
1·30 (0·18    9·26)
UK−TIA 109 108
(1·70%/y) (1·66%/y)
1·02 (0·67    1·57)
Reuther 0 1
(0·00%/y) (1·72%/y)
CA Co−op 4 8
(1·05%/y) (2·13%/y)
0·50 (0·11    2·23)
Toulouse TIA 2 3
(0·47%/y) (0·61%/y)
0·70 (0·07    6·99)
AICLA 1 3
(0·17%/y) (0·51%/y)
0·38 (0·03    4·96)
Danish Co−op 4 6
(1·49%/y) (2·25%/y)
0·68 (0·13    3·45)
Britton 6 9
(1·28%/y) (1·96%/y)
0·66 (0·17    2·49)
Danish Low Dose 9 5
(3·19%/y) (1·74%/y)
1·80 (0·45    7·13)
SALT 21 33
(1·05%/y) (1·65%/y)
0·64 (0·32    1·29)
160 179(1·44%/y) (1·59%/y)
0·87 (0·69   1·11)
P = 0·3
  (b) Subtotal
Heterogeneity between 10 trials: χ2
 9 = 7·3; P = 0·6
ESPS−II 30 26
(0·91%/y) (0·79%/y)
1·16 (0·58    2·32)
614 696(2·59%/y) (2·92%/y) 0·87 (0·78 

 0·98)
P = 0·02
  Total (a+b)
Adjusted
Web Figure 10: CHD DEATH in secondary prevention trials, by study 
99% or 95% confidence intervals
0·5 0·75 1·0 1·25 1·5
Aspirin better Aspirin worse
Treatment effect P = 0·02
Difference between
treatment effects in 2 subtotals: χ2
 1 = 0·0; P = 1·0
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Study
Events (% per annum)
Allocated
aspirin control
Ratio of annual event rates (& CI)
Aspirin : Control
(a) Post myocardial infarction
Cardiff−I 55 74
(8·50%/y) (11·97%/y)
0·72 (0·46    1·13)
Cardiff−II 124 182
(16·40%/y) (24·36%/y)
0·66 (0·48    0·91)
Paris−I 118 154
(4·73%/y) (6·40%/y)
0·73 (0·49    1·09)
AMIS 346 361
(5·22%/y) (5·54%/y)
0·92 (0·76    1·12)
CDP−A 65 81
(4·95%/y) (6·20%/y)
0·80 (0·52    1·22)
Gamis 24 37
(5·77%/y) (9·14%/y)
0·61 (0·30    1·21)
732 889(5·97%/y) (7·41%/y) 0·80 (0·73 

 0·89)
P = 0·00003
  (a) Subtotal
Heterogeneity between 6 trials: χ2
 5 = 7·8; P = 0·2
Micristin 34 66
(2·53%/y) (4·94%/y)
0·50 (0·29    0·85)
(b) Post transient ischaemic attack or stroke
AITIA 10 7
(4·52%/y) (3·47%/y)
1·40 (0·39    5·06)
UK−TIA 155 180
(2·46%/y) (2·85%/y)
0·86 (0·61    1·22)
Reuther 0 1
(0·00%/y) (1·72%/y)
CA Co−op 8 8
(2·12%/y) (2·15%/y)
0·97 (0·27    3·53)
Toulouse TIA 2 5
(0·47%/y) (1·03%/y)
0·44 (0·06    3·11)
AICLA 3 12
(0·52%/y) (2·11%/y)
0·30 (0·08    1·14)
Danish Co−op 6 14
(2·28%/y) (5·67%/y)
0·44 (0·14    1·39)
Britton 21 21
(4·63%/y) (4·71%/y)
0·98 (0·44    2·17)
Danish Low Dose 9 7
(3·20%/y) (2·45%/y)
1·30 (0·36    4·72)
SALT 49 70
(2·52%/y) (3·63%/y)
0·70 (0·43    1·12)
263 325(2·41%/y) (2·98%/y) 0·79 (0·66 

 0·95)
P = 0·01
  (b) Subtotal
Heterogeneity between 10 trials: χ2
 9 = 10·5; P = 0·3
ESPS−II 47 48
(1·43%/y) (1·46%/y)
0·98 (0·57    1·67)
995 1214(4·30%/y) (5·30%/y) 0·80 (0·73 

 0·88)
P < 0·00001
  Total (a+b)
Adjusted
Web Figure 11: MAJOR CORONARY EVENTS in secondary prevention trials, by study
99% or 95% confidence intervals
0·5 0·75 1·0 1·25 1·5
Aspirin better Aspirin worse
Treatment effect P < 0·00001
Difference between
treatment effects in 2 subtotals: χ2
 1 = 0·0; P = 0·9
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Study
Events (% per annum)
Allocated
aspirin control
Ratio of annual event rates (& CI)
Aspirin : Control
(a) Post myocardial infarction
Cardiff−I 1 0
(0·15%/y) (0·00%/y)
Cardiff−II 2 0
(0·26%/y) (0·00%/y)
Paris−I 0 0
(0·00%/y) (0·00%/y)
AMIS 0 1
(0·00%/y) (0·01%/y)
CDP−A 0 1
(0·00%/y) (0·07%/y)
Gamis 0 2
(0·00%/y) (0·49%/y)
3 4(0·02%/y) (0·03%/y)
0·74 (0·17    3·27)
P = 0·7
  (a) Subtotal
Heterogeneity between 5 trials: χ2
 4 = 6·9; P = 0·1
Micristin 8 10
(0·60%/y) (0·75%/y)
0·79 (0·23   2·69)
(b) Post transient ischaemic attack or stroke
AITIA 1 0
(0·47%/y) (0·00%/y)
UK−TIA 14 4
(0·23%/y) (0·07%/y)
2·52 (0·64   9·92)
Reuther 0 1
(0·00%/y) (1·79%/y)
CA Co−op 0 0
(0·00%/y) (0·00%/y)
Toulouse TIA 0 0
(0·00%/y) (0·00%/y)
AICLA 2 2
(0·37%/y) (0·37%/y)
0·99 (0·08   13·03)
Danish Co−op 1 1
(0·41%/y) (0·41%/y)
Britton 3 3
(0·68%/y) (0·69%/y)
0·99 (0·12   8·07)
Danish Low Dose 1 0
(0·36%/y) (0·00%/y)
SALT 11 4
(0·58%/y) (0·22%/y)
2·48 (0·66   9·38)
33 15(0·32%/y) (0·14%/y)
1·90 (1·06    3·44)
adverse
P = 0·03
  (b) Subtotal
Heterogeneity between 8 trials: χ2
 7 = 4·5; P = 0·7
ESPS−II 9 10
(0·27%/y) (0·30%/y)
0·90 (0·28   2·94)
36 19(0·16%/y) (0·08%/y)
1·67 (0·97    2·90)
adverse
P = 0·07
  Total (a+b)
Adjusted
Web Figure 12: HAEMORRHAGIC STROKE in secondary prevention trials, by study 
99% or 95% confidence intervals
0·1 0·25 0·5 1·0 2·5 5·0 10
Aspirin better Aspirin worse
Treatment effect P = 0·07, adverse
Difference between
treatment effects in 2 subtotals: χ2
 1 = 1·3; P = 0·2
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Study
Events (% per annum)
Allocated
aspirin control
Ratio of annual event rates (& CI)
Aspirin : Control
(a) Post myocardial infarction
Cardiff−I 0 0
(0·00%/y) (0·00%/y)
Cardiff−II 0 1
(0·00%/y) (0·13%/y)
Paris−I 2 0
(0·08%/y) (0·00%/y)
AMIS 0 3
(0·00%/y) (0·04%/y)
CDP−A 0 0
(0·00%/y) (0·00%/y)
Gamis 0 0
(0·00%/y) (0·00%/y)
2 4(0·02%/y) (0·03%/y)
0·35 (0·07    1·83)
P = 0·2
  (a) Subtotal
Heterogeneity between 3 trials: χ2
 2 = 4·0; P = 0·1
Micristin 9 15
(0·67%/y) (1·12%/y)
0·60 (0·21   1·73)
(b) Post transient ischaemic attack or stroke
AITIA 0 0
(0·00%/y) (0·00%/y)
UK−TIA 48 64
(0·80%/y) (1·07%/y)
0·74 (0·40   1·36)
Reuther 0 1
(0·00%/y) (1·79%/y)
CA Co−op 0 0
(0·00%/y) (0·00%/y)
Toulouse TIA 0 0
(0·00%/y) (0·00%/y)
AICLA 0 0
(0·00%/y) (0·00%/y)
Danish Co−op 1 0
(0·41%/y) (0·00%/y)
Britton 21 21
(4·74%/y) (4·83%/y)
0·98 (0·44   2·17)
Danish Low Dose 0 0
(0·00%/y) (0·00%/y)
SALT 68 86
(3·59%/y) (4·69%/y)
0·77 (0·51   1·16)
138 172(1·32%/y) (1·66%/y) 0·79 (0·62 
 
 1·00)
P = 0·05
  (b) Subtotal
Heterogeneity between 5 trials: χ2
 4 = 2·6; P = 0·6
ESPS−II 122 158
(3·70%/y) (4·79%/y)
0·76 (0·55   1·04)
140 176(0·61%/y) (0·77%/y) 0·78 (0·61 
 
 0·99)
P = 0·04
  Total (a+b)
Adjusted
Web Figure 13: DEFINITELY ISCHAEMIC STROKE in secondary prevention trials, by study  
99% or 95% confidence intervals
0·5 0·75 1·0 1·25 1·5
Aspirin better Aspirin worse
Treatment effect P = 0·04
Difference between
treatment effects in 2 subtotals: χ2
 1 = 0·9; P = 0·3
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Study
Events (% per annum)
Allocated
aspirin control
Ratio of annual event rates (& CI)
Aspirin : Control
(a) Post myocardial infarction
Cardiff−I 0 0
(0·00%/y) (0·00%/y)
Cardiff−II 5 3
(0·64%/y) (0·38%/y)
1·67 (0·27    10·32)
Paris−I 12 16
(0·46%/y) (0·63%/y)
0·73 (0·21    2·49)
AMIS 39 61
(0·57%/y) (0·90%/y)
0·62 (0·37    1·03)
CDP−A 13 11
(0·97%/y) (0·82%/y)
1·18 (0·41    3·39)
Gamis 0 0
(0·00%/y) (0·00%/y)
69 91(0·55%/y) (0·73%/y) 0·74 (0·54 

 1·02)
P = 0·06
  (a) Subtotal
Heterogeneity between 4 trials: χ2
 3 = 3·5; P = 0·3
Micristin 9 15
(0·67%/y) (1·12%/y)
0·60 (0·21    1·73)
(b) Post transient ischaemic attack or stroke
AITIA 12 27
(5·58%/y) (14·14%/y)
0·40 (0·17    0·97)
UK−TIA 187 234
(3·11%/y) (3·92%/y)
0·79 (0·57    1·08)
Reuther 2 3
(3·45%/y) (5·36%/y)
0·67 (0·07    6·67)
CA Co−op 23 20
(6·55%/y) (5·76%/y)
1·13 (0·51    2·47)
Toulouse TIA 7 9
(1·67%/y) (1·86%/y)
0·82 (0·23    2·99)
AICLA 18 31
(3·30%/y) (5·76%/y)
0·59 (0·28    1·22)
Danish Co−op 17 13
(7·05%/y) (5·28%/y)
1·34 (0·52    3·44)
Britton 28 29
(6·32%/y) (6·67%/y)
0·95 (0·48    1·87)
Danish Low Dose 8 12
(2·91%/y) (4·41%/y)
0·66 (0·21    2·09)
SALT 73 92
(3·85%/y) (5·02%/y)
0·77 (0·52    1·15)
375 470(3·58%/y) (4·53%/y) 0·78 (0·68 

 0·91)
P = 0·001
  (b) Subtotal
Heterogeneity between 10 trials: χ2
 9 = 9·2; P = 0·4
ESPS−II 188 225
(5·70%/y) (6·82%/y)
0·81 (0·62    1·07)
444 561(1·93%/y) (2·46%/y) 0·78 (0·68 

 0·89)
P = 0·0002
  Total (a+b)
Adjusted
Web Figure 14: PROBABLY ISCHAEMIC STROKE in secondary prevention trials, by study
 
99% or 95% confidence intervals
0·5 0·75 1·0 1·25 1·5
Aspirin better Aspirin worse
Treatment effect P = 0·0002
Difference between
treatment effects in 2 subtotals: χ2
 1 = 0·1; P = 0·7
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Study
Events (% per annum)
Allocated
aspirin control
Ratio of annual event rates (& CI)
Aspirin : Control
(a) Post myocardial infarction
Cardiff−I 1 0
(0·15%/y) (0·00%/y)
Cardiff−II 7 3
(0·90%/y) (0·38%/y)
2·25 (0·44    11·47)
Paris−I 12 16
(0·46%/y) (0·63%/y)
0·73 (0·21    2·49)
AMIS 39 62
(0·57%/y) (0·92%/y)
0·61 (0·36    1·02)
CDP−A 13 12
(0·97%/y) (0·90%/y)
1·08 (0·39    3·04)
Gamis 0 2
(0·00%/y) (0·49%/y)
72 95(0·57%/y) (0·76%/y) 0·74 (0·54 

 1·01)
P = 0·06
  (a) Subtotal
Heterogeneity between 6 trials: χ2
 5 = 7·8; P = 0·2
Micristin 17 25
(1·26%/y) (1·87%/y)
0·67 (0·30    1·50)
(b) Post transient ischaemic attack or stroke
AITIA 13 27
(6·05%/y) (14·14%/y)
0·43 (0·18    1·04)
UK−TIA 201 238
(3·34%/y) (3·99%/y)
0·83 (0·61    1·13)
Reuther 2 4
(3·45%/y) (7·14%/y)
0·51 (0·06    4·18)
CA Co−op 23 20
(6·55%/y) (5·76%/y)
1·13 (0·51    2·47)
Toulouse TIA 7 9
(1·67%/y) (1·86%/y)
0·82 (0·23    2·99)
AICLA 20 33
(3·67%/y) (6·13%/y)
0·61 (0·30    1·24)
Danish Co−op 18 14
(7·47%/y) (5·69%/y)
1·32 (0·53    3·27)
Britton 31 32
(7·00%/y) (7·36%/y)
0·95 (0·50    1·82)
Danish Low Dose 9 12
(3·27%/y) (4·41%/y)
0·74 (0·24    2·28)
SALT 84 96
(4·43%/y) (5·23%/y)
0·85 (0·58    1·25)
408 485(3·90%/y) (4·68%/y) 0·83 (0·72 

 0·96)
P = 0·01
  (b) Subtotal
Heterogeneity between 10 trials: χ2
 9 = 8·4; P = 0·5
ESPS−II 197 235
(5·97%/y) (7·13%/y)
0·82 (0·63    1·07)
480 580(2·08%/y) (2·54%/y) 0·81 (0·71 

 0·92)
P = 0·002
  Total (a+b)
Adjusted
Web Figure 15: ANY STROKE in secondary prevention trials, by study 
99% or 95% confidence intervals
0·5 0·75 1·0 1·25 1·5
Aspirin better Aspirin worse
Treatment effect P = 0·002
Difference between
treatment effects in 2 subtotals: χ2
 1 = 0·4; P = 0·5
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Study
Deaths (% per annum)
Allocated
aspirin control
Ratio of annual death rates (& CI)
Aspirin : Control
(a) Post myocardial infarction
Cardiff−I 47 61
(7·18%/y) (9·62%/y)
0·75 (0·46    1·23)
Cardiff−II 98 122
(12·63%/y) (15·60%/y)
0·82 (0·58    1·16)
Paris−I 73 90
(2·81%/y) (3·50%/y)
0·80 (0·49    1·33)
AMIS 214 199
(3·12%/y) (2·91%/y)
1·04 (0·81    1·34)
CDP−A 43 61
(3·21%/y) (4·53%/y)
0·71 (0·43    1·18)
Gamis 22 30
(5·24%/y) (7·30%/y)
0·70 (0·33    1·47)
497 563(3·93%/y) (4·48%/y) 0·87 (0·77 

 0·99)
P = 0·03
  (a) Subtotal
Heterogeneity between 6 trials: χ2
 5 = 5·9; P = 0·3
Micristin 34 56
(2·53%/y) (4·19%/y)
0·59 (0·34    1·03)
(b) Post transient ischaemic attack or stroke
AITIA 10 13
(4·42%/y) (6·34%/y)
0·73 (0·24    2·22)
UK−TIA 180 172
(2·81%/y) (2·64%/y)
1·06 (0·76    1·48)
Reuther 0 3
(0·00%/y) (5·17%/y)
CA Co−op 11 15
(2·89%/y) (4·00%/y)
0·71 (0·26    1·96)
Toulouse TIA 7 7
(1·64%/y) (1·43%/y)
1·04 (0·26    4·14)
AICLA 13 12
(2·26%/y) (2·04%/y)
1·11 (0·40    3·11)
Danish Co−op 8 8
(2·97%/y) (3·00%/y)
1·01 (0·28    3·65)
Britton 28 29
(6·00%/y) (6·30%/y)
0·95 (0·48    1·88)
Danish Low Dose 13 7
(4·61%/y) (2·44%/y)
1·85 (0·59    5·87)
SALT 58 67
(2·90%/y) (3·36%/y)
0·87 (0·55    1·37)
328 333(2·96%/y) (2·96%/y)
0·98 (0·83   1·16)
P = 0·8
  (b) Subtotal
Heterogeneity between 10 trials: χ2
 9 = 7·1; P = 0·6
ESPS−II 118 124
(3·58%/y) (3·76%/y)
0·95 (0·67    1·34)
825 896(3·47%/y) (3·76%/y) 0·91 (0·82 

 1·00)
P = 0·06
  Total (a+b)
Adjusted
Web Figure 16: VASCULAR DEATH in secondary prevention trials, by study 
99% or 95% confidence intervals
0·5 0·75 1·0 1·25 1·5
Aspirin better Aspirin worse
Treatment effect P = 0·06
Difference between
treatment effects in 2 subtotals: χ2
 1 = 1·1; P = 0·3
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Study
Events (% per annum)
Allocated
aspirin control
Ratio of annual event rates (& CI)
Aspirin : Control
(a) Post myocardial infarction
Cardiff−I − −
Cardiff−II − −
Paris−I − −
AMIS − −
CDP−A − −
Gamis − −
− −  (a) Subtotal
Micristin 3 3
(0·22%/y) (0·22%/y)
0·99 (0·12    8·18)
(b) Post transient ischaemic attack or stroke
AITIA 3 0
(1·33%/y) (0·00%/y)
UK−TIA 14 2
(0·22%/y) (0·03%/y)
3·36 (0·82    13·71)
Reuther 0 1
(0·00%/y) (1·75%/y)
CA Co−op − −
Toulouse TIA − −
AICLA − −
Danish Co−op − −
Britton 3 2
(0·65%/y) (0·44%/y)
1·46 (0·15    14·65)
Danish Low Dose − −
SALT 3 1
(0·15%/y) (0·05%/y)
2·74 (0·21    35·99)
23 6(0·25%/y) (0·06%/y)
2·69 (1·25   5·76)
adverse
P = 0·01
  (b) Subtotal
Heterogeneity between 5 trials: χ2
 4 = 3·6; P = 0·5
ESPS−II 20 12
(0·61%/y) (0·36%/y)
1·66 (0·66    4·14)
23 6(0·25%/y) (0·06%/y)
2·69 (1·25   5·76)
adverse
P = 0·01
  Total (a+b)
Adjusted
Web Figure 17: GASTRO−INTESTINAL BLEED (or other extracranial bleed) in secondary prevention trials, 
 that reported at least one such event
99% or 95% confidence intervals
0·1 0·25 0·5 1·0 2·5 5·0 10
Aspirin better Aspirin worse
Treatment effect P = 0·01, adverse
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Study
Events/Patients
Allocated
aspirin control
Ratio of annual event rates (& CI)
Aspirin : Control
(a) Primary prevention (χ2
 5 = 4·3; P = 0·5)
British Doctors’ Study 291/3429 2×(143/1710)
(8·5%) (8·4%)
1·01 (0·78    1·31)
US Physicians’ Health
Study
313/11037 373/11034
(2·8%) (3·4%)
0·84 (0·69    1·02)
Thrombosis Prevention
Trial
215/2545 253/2540
(8·4%) (10·0%)
0·84 (0·67    1·07)
Hypertension Optimal
Treatment Trial
329/9399 383/9391
(3·5%) (4·1%)
0·85 (0·70    1·04)
Primary Prevention Project 46/2226 66/2269
(2·1%) (2·9%)
0·71 (0·43    1·15)
Women’s Health Study 477/19934 522/19942
(2·4%) (2·6%)
0·91 (0·77    1·07)
1671/
48570
1883/
48596(3·4%) (3·9%)
0·88 (0·82   0·94)
P = 0·0001
  (a) Subtotal
(b) Post myocardial infarction (χ2
 5 = 4·7; P = 0·5)
Cardiff−I 57/615 76/624
(9·3%) (12·2%)
0·72 (0·46    1·13)
Cardiff−II 129/847 187/878
(15·2%) (21·3%)
0·70 (0·52    0·93)
Paris−I 130/810 2×(82/406)
(16·0%) (20·2%)
0·76 (0·52    1·10)
AMIS 382/2267 413/2257
(16·9%) (18·3%)
0·89 (0·74    1·06)
CDP−A 76/758 102/771
(10·0%) (13·2%)
0·74 (0·50    1·09)
Gamis 33/317 45/309
(10·4%) (14·6%)
0·68 (0·37    1·27)
807/
5614
987/
5651(14·4%) (17·5%)
0·79 (0·72   0·87)
P < 0·00001
  (b) Subtotal
Micristin 65/672 106/668
(9·7%) (15·9%)
0·57 (0·38    0·87)
(c) Post TIA or stroke (χ2
 9 = 6·3; P = 0·7)
AITIA 26/162 35/157
(16·0%) (22·3%)
0·67 (0·32    1·39)
UK−TIA 354/1621 2×(204/814)
(21·8%) (25·1%)
0·85 (0·67    1·07)
Reuther 2/30 5/30
(6·7%) (16·7%)
0·42 (0·06    2·96)
CA Co−op 33/144 30/139
(22·9%) (21·6%)
1·08 (0·57    2·08)
Toulouse TIA 11/147 16/156
(7·5%) (10·3%)
0·73 (0·27    1·96)
AICLA 31/198 48/204
(15·7%) (23·5%)
0·63 (0·35    1·12)
Danish Co−op 23/101 27/102
(22·8%) (26·5%)
0·84 (0·41    1·75)
Britton 59/253 55/252
(23·3%) (21·8%)
1·05 (0·65    1·71)
Danish Low Dose 21/150 21/151
(14·0%) (13·9%)
0·98 (0·44    2·18)
SALT 138/676 169/683
(20·4%) (24·7%)
0·79 (0·59    1·06)
698/
3482
814/
3502(20·0%) (23·2%)
0·83 (0·75   0·93)
P = 0·001
  (c) Subtotal
ESPS−II 293/1649 332/1649
(17·8%) (20·1%)
0·86 (0·68    1·08)
3176/
57666
3684/
57749(5·5%) (6·4%)
0·85 (0·80   0·89)
P < 0·00001
  Total (a+b+c)
Adjusted
Web Figure 17: SERIOUS VASCULAR EVENTS in primary and secondary prevention trials 
by study
99% or 95% confidence intervals
0 0·5 1·0 1·5 2·0
Aspirin better Aspirin worse
Treatment effect P < 0·00001Heterogeneity between 24 trials: χ2
 23 = 32·7; P = 0·09
Heterogeneity between 3 subtotals: χ2
 2 = 2·8; P = 0·2
Heterogeneity within subtotals: χ2
 21 = 29·8; P = 0·10
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Statistical Appendix 
 
Estimating the event rate ratio associated with baseline prognostic factors for selected major outcomes 
among the 94 000 people without prior vascular disease at baseline (see table 3 and webtable 3) 
 
Among patients without prior vascular disease, the event rate ratio for selected major outcomes (serious vascular 
event; non-fatal MI; CHD death; major coronary event; probable ischaemic stroke; haemorrhagic stroke; total 
stroke and major gastrointestinal [or other extracranial] bleed) associated with baseline prognostic factors was 
modelled as follows. For patient i in study j receiving treatment k (where k=0 corresponds to placebo and k=1 
corresponds to aspirin), let Yijk denote the occurrence or otherwise for that patient of the outcome under 
consideration during the trial, and let Tijk denote the number of years of follow-up. The logarithm of the expected 
annual event rate was modelled through the Poisson regression model:  
 
 
 
where αj is the average (log) annual event rate observed in the placebo group in study j,          is the vector of 
baseline characteristics for patient i in study j (including an indicator variable corresponding to randomisation to 
aspirin),          is the vector of mean baseline risk exposure levels observed among the placebo patients in study j, 
and     is the vector of regression coefficients (including a regression coefficient associated with aspirin 
allocation).  In addition to aspirin allocation, the baseline prognostic factors included in each model were: age 
(per decade); male gender; history of diabetes; cigarette smoking status (current vs ex/never); total cholesterol 
(per 1 mmol/L); the average of systolic and diastolic blood pressure (per 20 mmHg) and body mass index (per 5 
kg/m2).  Missing values of baseline characteristics were imputed based on the study-specific average levels in the 
placebo group        .  For the British Doctors' Study, in which total cholesterol was not available, the mean value 
across all the other trials was used.  
 
 
Separating individuals at “very low”, “low”, “moderate” and “high” predicted risk of a major coronary 
event for the analysis in figure 7, and the subgroup analyses (figure 2 and the corresponding webfigures 
[1, 4, 5 & 7])  
 
For major coronary events, the log event rate ratios     described above were re-estimated based on the 47 000 
patients in the control groups only (so patients allocated aspirin and the term associated with aspirin allocation 
were removed). These log event rate ratios (which were similar to those estimated among all participants) were 
then used in conjunction with the estimated average (log) annual event rates                    in the six trials to 
predict the average 5-yearly major coronary event risk Pijk that would be expected in the absence of aspirin use, 
where 
 
 
 
and 
 
 
 
Individuals were categorised as “very low” (<2.5%), “low” (2.5-5%), “moderate” (5-10%), or “high” (≥10%) 
predicted 5-year risk of a major coronary event without aspirin on the basis of Pijk. (Note that the regression 
model may have slightly overestimated risk in the small high risk group.) The proportional and absolute effects 
of aspirin allocation on specific endpoints was then estimated separately within each of these subgroups (as 
described in the main Statistical Methods section). 
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